nach oben

Die Ophthalmologie

Erschienen in:

16.12.2020 | Netzhautablösung | Leitthema

Proliferative Vitreoretinopathie-Prozess – „To heal or not to heal“

verfasst von: Univ.-Prof. Dr. S. Grisanti, S. Priglinger, L. Hattenbach

Erschienen in: Die Ophthalmologie | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Die proliferative Vitreoretinopathie (PVR) ist nach einem halben Jahrhundert Forschungstätigkeit weiterhin ein ungelöstes Problem.

Methoden

Es folgt ein Übersichtsbeitrag zu den Mechanismen der PVR im Kontext der „Wundheilungsforschung“.

Ergebnisse

Wundheilung ist ein physiologischer Reparaturmechanismus, der in allen Organen in ähnlicher Weise stattfindet und narbige Veränderungen hinterlassen kann. Die PVR basiert auf diesem Mechanismus. Die Besonderheit dieses Prozesses und seiner Folgen ergibt sich durch die Lokalisation und die beteiligten Strukturen. Die bisherigen medikamentösen Ansätze waren nicht ausreichend wirksam. Das wachsende Verständnis um die Mechanismen der narbenfreien fetalen Wundheilung könnte aber zur Lösung des PVR-Problems führen.

Schlussfolgerung

Die PVR ist ein physiologischer Prozess mit pathologischem Ergebnis. Die komplexen Schritte, die sukzessive ihren Beitrag zum Wundheilungsprozess leisten, sind gut verstanden. Eine Modifikation dieser Schritte, um den ursprünglichen Zustand wieder herzustellen, ist gegenwärtig weder in der Augenheilkunde noch in anderen medizinischen Fächern gelungen, aber möglich.

Machemer R, Aaberg TM, Freeman HM et al (1991) An updated classification of retinal detachment with proliferative vitreoretinopathy. Am J Ophthalmol 112:159–165PubMedCrossRef

de la Rua ER, Pastor JC, Fernandez I et al (2008) Non-complicated retinal detachment management: variations in 4 years. Retina 1 project; report 1. Br J Ophthalmol 92:523–525PubMedCrossRef

Girard P, Mimoun G, Karpouzas I et al (1994) Clinical risk factors for proliferative vitreoretinopathy after retinal detachment surgery. Retina 14:417–424PubMedCrossRef

Duquesne N, Bonnet M, Adeleine P (1996) Preoperative vitreous hemorrhage associated with rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol 234:677–682PubMedCrossRef

Yanyali A, Bonnet M (1996) Risk factors of postoperative proliferative vitreoretinopathy in giant tears. J Fr Ophtalmol 19:175–180PubMed

Patel NN, Bunce C, Asaria RH, Charteris DG (2004) Resources involved in managing retinal detachment complicated by proliferative vitreoretinopathy. Retina 24:883PubMedCrossRef

Kim IK, Arroyo JG (2002) Mechanisms in proliferative vitreoretinopathy. Ophthalmol Clin North Am 15:81–86PubMedCrossRef

Tseng W, Cortez RT, Ramirez G et al (2004) Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol 137:1105–1115PubMedCrossRef

Campochiaro PA, Kaden IH, Vidaurri-Leal J et al (1985) Cryotherapy enhances intravitreal dispersion of viable retinal pigment epithelial cells. Arch Ophthalmol 103:434–436PubMedCrossRef

10.

Bonnet M, Guenoun S (1995) Surgical risk factors for severe postoperative proliferative vitreoretinopathy (PVR) in retinal detachment with grade B PVR. Graefes Arch Clin Exp Ophthalmol 233:789–791PubMedCrossRef

11.

Bonnet M, Fleury J, Guenoun S et al (1996) Cryopexy in primary rhegmatogenous retinal detachment: a risk factor for postoperative proliferative vitreoretinopathy? Graefes Arch Clin Exp Ophthalmol 234:739–743PubMedCrossRef

12.

Sanabria Ruiz-Colmenares MR, Pastor Jimeno JC, Garrote Adrados JA et al (2006) Cytokine gene polymorphisms in retinal detachment patients with and without proliferative vitreoretinopathy: a preliminary study. Acta Ophthalmol Scand 84:309–313PubMedCrossRef

13.

Rojas J, Fernandez I, Pastor JC et al (2010) A strong genetic association between the tumor necrosis factor locus and proliferative vitreoretinopathy: The Retina 4 Project. Ophthalmology 117:2417–2423PubMedCrossRef

14.

Rojas J, Fernandez I, Pastor JC et al (2013) A genetic case-control study confirms the implication of SMAD7 and TNF locus in the development of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 54:1665–1678PubMedCrossRef

15.

Pastor-Idoate S, Rodriguez-Hernandez I, Rojas J et al (2013) The p53 codon 72 polymorphism (rs1042522) is associated with proliferative vitreoretinopathy: the Retina 4 Project. Ophthalmology 120:623–628PubMedCrossRef

16.

Pastor-Idoate S, Rodriguez-Hernandez I, Rojas J et al (2013) The T309G MDM2 gene polymorphism is a novel risk factor for proliferative Vitreoretinopathy. PLoS One 12:e82283CrossRef

17.

Anonymous (1983) The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology 90:121–125CrossRef

18.

Heimann K, Wiedemann P (1989) Cologne classification of proliferative vitreoretinopathy. In: Heimann K, Wiedemann P (Hrsg) Proliferative Vitreoretinopathy. Kaden, Heidelberg, S 148–149

19.

Lean SW, Stern WH, Irvine AR et al (1989) Classification of proliferative vitrereotinopathy used in the silicone study. Ophthalmology 96:765–771PubMedCrossRef

20.

Di Lauro S, Kadhim MR, Charteris DG, Pastor JC (2016) Classifications for proliferative vitreoretinopathy (PVR): an analysis of their use in publications over the last 15 years. J Ophthalmol 2016:7807596PubMedPubMedCentralCrossRef

21.

Wilkins RB, Kulwin DR (1979) Wendell L. Hughes lecture: wound healing. Ophthalmology 86:507–510PubMedCrossRef

22.

Mietz H, Heimann K (1995) Onset and recurrence of proliferative vitreoretinopathy in various vitreoretinal disease. Br J Ophthalmol 79:874–877PubMedPubMedCentralCrossRef

23.

Wiedemann P (1992) Growth factors in retinal diseases: proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol 36:373–384PubMedCrossRef

24.

Moysidis SN, Thanos A, Vavvas DG (2012) Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Mediators Inflamm 2012:815937PubMedPubMedCentralCrossRef

25.

Abu El-Asrar AM, Struyf S, Van Damme J et al (2008) Circulating fibrocytes contribute to the myofibroblast population in proliferative vitreoretinopathy epiretinal membranes. Br J Ophthalmol 92:699–704PubMedCrossRef

26.

Lin ML, Li YP, Li ZR et al (2011) Macrophages acquire fibroblast characteristics in a rat model of proliferative vitreoretinopathy. Ophthalmic Res 45:180–190PubMedCrossRef

27.

Sakamoto T, Ishibashi T (2011) Hyalocytes: essential cells of the vitreous cavity in vitreoretinal pathophysiology? Retina 31:222–228PubMedCrossRef

28.

Hiscott PS, Grierson I, McLeod D (1985) Natural history of fibrocellular epiretinal membranes: a quantitative, autoradiographic, and immunohistochemical study. Br J Ophthalmol 69:810–823PubMedPubMedCentralCrossRef

29.

Ioachim E, Stefaniotou M, Gorezis S et al (2005) Immunohistochemical study of extracellular matrix components in epiretinal membranes of vitreoproliferative retinopathy and proliferative diabetic retinopathy. Eur J Ophthalmol 15:384–391PubMedCrossRef

30.

Grisanti S, Guidry C (1995) Transdifferentiation of retinal pigment epithelial cells from epithelial to mesenchymal phenotype. Invest Ophthalmol Vis Sci 36:391–405PubMed

31.

Guidry C (2005) The role of Müller cells in fibrocontractive retinal disorders. Prog Retin Eye Res 24:75–86PubMedCrossRef

32.

Sramek SJ, Wallow IH, Stevens TS et al (1989) Immunostaining of preretinal membranes for actin, fibronectin, and glial fibrillary acidic protein. Ophthalmology 96:835–841PubMedCrossRef

33.

McGillem GS, Dacheux RF (1999) Rabbit retinal Müller cells undergo antigenic changes in response to experimentally induced proliferative vitreoretinopathy. Exp Eye Res 68:617–627PubMedCrossRef

34.

Garcia S, Lopez E, Lopez-Colome AM (2008) Glutamate accelerates RPE cell proliferation through ERK1/2 activation via distinct receptor-specific mechanisms. J Cell Biochem 104:377–390PubMedCrossRef

35.

Tamiya S, Liu L, Kaplan HJ (2010) Epithelial-mesenchymal transition and proliferation of retinal pigment epithelial cells initiated upon loss of cell-cell contact. Invest Ophthalmol Vis Sci 51:2755–2763PubMedCrossRef

36.

Pratt CH, Vadigepalli R, Chakravarthula P et al (2008) Transcriptional regulatory network analysis during epithelial-mesenchymal transformation of retinal pigment epithelium. Mol Vis 14:1414–1428PubMedPubMedCentral

37.

Lee H, O’Meara SJ, O’Brien C et al (2007) The role of gremlin, a BMP antagonist, and epithelial-to-mesenchymal transition in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 48:4291–4299PubMedCrossRef

38.

Willis BC, DuBois RM, Borok Z (2006) Epithelial origin of myofibroblasts during fibrosis in the lung. Proc Am Thorac Soc 3:377–382PubMedPubMedCentralCrossRef

39.

Guarino M (2007) Epithelial-mesenchymal transition and tumour invasion. Int J Biochem Cell Biol 39:2153–2160PubMedCrossRef

40.

Raghu K, Eric GN (2003) Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112:1776–1784CrossRef

41.

Zeisberg M, Kalluri R (2004) The role of epithelial-to-mesenchymal transition in renal fibrosis. J Mol Med 82:175–181PubMedCrossRef

42.

Choi J, Park SY, Joo CK (2007) Transforming growth factor-beta 1 represses ecadherin production via slug expression in lens epithelial cells. Invest Ophthalmol Vis Sci 48:2708–2718PubMedCrossRef

43.

Beutel J, Luke M, Bartz-Schmidt KU et al (2009) Vitreal-induced RPE cell traction. Investigation of pathological vitreous samples in an in vitro contraction model. Ophthalmologe 106:893–898PubMedCrossRef

44.

Bringmann A, Wiedemann P (2009) Involvement of Muller glial cells in epiretinal membrane formation. Graefes Arch Clin Exp Ophthalmol 247:865–883PubMedCrossRef

45.

Bringmann A, Pannicke T, Grosche J et al (2006) Muller cells in the healthy and diseased retina. Prog Retin Eye Res 25:397–424PubMedCrossRef

46.

Charteris DG, Downie J, Aylward GW et al (2007) Intraretinal and periretinal pathology in anterior proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 245:93–100PubMedCrossRef

47.

Fisher SK, Lewis GP (2003) Muller cell and neuronal remodeling in retinal detachment and reattachment and their potential consequences for visual recovery: a review and reconsideration of recent data. Vision Res 43:887–897PubMedCrossRef

48.

Baudouin C, Fredj-Reygrobellet D, Brignole F, Negre F, Lapalus P et al (1993) Growth factors in vitreous and subretinal fluid cells from patients with proliferative reoretinopathy. Ophthalmic Res 25:52–59PubMedCrossRef

49.

Kita T, Hata Y, Kano K et al (2007) Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor. Diabetes 56:231–238PubMedCrossRef

50.

Winkler J, Hoerauf H (2011) TGF-β and RPE-derived cells in subretinal strands from patients with proliferative vitreoretinopathy. Eur J Ophthalmol 21:422–426PubMedCrossRef

51.

Lee H, O’Meara SJ, O’Brien C, Kane R (2007) The role of gremlin, a BMP antagonist, and epithelial-to-mesenchymal transition in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 48:4291–4299PubMedCrossRef

52.

Lee J, Ko M, Joo CK (2008) Rho plays a key role in TGF-beta 1‑induced cytoskeletal rearrangement in human retinal pigment epithelium. J Cell Physiol 216:520–526PubMedCrossRef

53.

Oshima Y, Sakamoto T, Hisatomi T et al (2002) Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy. Gene Ther 9:1214–1220PubMedCrossRef

54.

Itoh Y, Kimoto K, Imaizumi M et al (2007) Inhibition of RhoA/Rho-kinase pathway suppresses the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells. Exp Eye Res 84:464–472PubMedCrossRef

55.

Kita T (2010) Molecular mechanisms of preretinal membrane contraction in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Nippon Ganka Gakkai Zasshi 114:927–934PubMed

56.

Nassar K, Grisanti S, Tura A et al (2014) A TGF‑β receptor 1 inhibitor for prevention of proliferative vitreoretinopathy. Exp Eye Res 123:72–78PubMedCrossRef

57.

Nassar K, Lüke J, Lüke M et al (2010) The novel use of decorin in prevention of the development of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol 249:1649–1660CrossRef

58.

Abdullatif AM, Macky TA, Abdullatif MM (2018) Intravitreal decorin preventing proliferative vitreoretinopathy in perforating injuries: a pilot study. Graefes Arch Clin Exp Ophthalmol 256:2473–2481PubMedCrossRef

59.

Lei H, Hovland P, Velez G et al (2007) A potential role for PDGF‑C in experimental and clinical proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 48:2335–2342PubMedCrossRef

60.

Cui JZ, Chiu A, Maberley D et al (2007) Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye 21:200–208PubMedCrossRef

61.

Li R, Maminishkis A, Wang FE et al (2007) PDGF‑C and -D induced proliferation/migration of human RPE is abolished by inflammatory cytokines. Invest Ophthalmol Vis Sci 48:5722–5732PubMedCrossRef

62.

Moon SW, Chung EJ, Jung SA et al (2009) PDGF stimulation of Muller cell proliferation: contributions of c‑JNK and the PI3K/Akt pathway. Biochem Biophys Res Commun 388:167–171PubMedCrossRef

63.

Cui J, Lei H, Samad A et al (2009) PDGF receptors are activated in human epiretinal membranes. Exp Eye Res 88:438–444PubMedCrossRef

64.

Ikuno Y, Kazlauskas A (2002) An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor. Invest Ophthalmol Vis Sci 43:2406–2411PubMed

65.

Saishin Y, Takahashi K, Seo MS et al (2003) The kinase inhibitor PKC412 suppresses epiretinal membrane formation and retinal detachment in mice with proliferative retinopathies. Invest Ophthalmol Vis Sci 44:3656–3662PubMedCrossRef

66.

Kon CH, Occleston NL, Aylward GW et al (1999) Expression of vitreous cytokines in proliferative vitreoretinopathy: a prospective study. Invest Ophthalmol Vis Sci 40:705–712PubMed

67.

Hui Y, Shi Y, Zhang X et al (1999) TNF-alpha, IL‑8 and IL‑6 in the early inflammatory stage of experimental PVR model induced by macrophages. Zhonghua Yan Ke Za Zhi 35:140–143PubMed

68.

Wang LH, Li GL (2008) Progress in studies on effects of extracellular matrix in occurrence of proliferative vitreoretinopathy. Zhonghua Yan Ke Za Zhi 44:759–763PubMed

69.

Tomasek JJ, Gabbiani G, Hinz B et al (2002) Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3:349–363PubMedCrossRef

70.

Hollborn M, Reichenbach A, Wiedemann P et al (2004) Contrary effects of cytokines on mRNAs of cell cycle- and ECM-related proteins in hRPE cells in vitro. Curr Eye Res 28:215–223PubMedCrossRef

71.

Hollborn M, Faude F, Wiedemann P et al (2003) Elevated proto-oncogene and collagen mRNA expression in PVR retinas. Graefes Arch Clin Exp Ophthalmol 241:439–446PubMedCrossRef

72.

Jerdan JA, Pepose JS, Michels RG et al (1989) Proliferativee vitreoretinopathy membranes. An immunohistochemical study. Ophthalmology 96:801–810PubMedCrossRef

73.

George B, Chen S, Chaudhary V et al (2009) Extracellular matrix proteins in epiretinal membranes and in diabetic retinopathy. Curr Eye Res 34:134–144PubMedCrossRef

74.

Glaser BM, Cardin A, Biscoe B (1987) Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction. Ophthalmology 94:327–332PubMedCrossRef

75.

Grisanti S, Wiedemann P, Weller M et al (1991) The significance of complement in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 32:2711–2717PubMed

76.

Yu J, Liu F, Cui SJ et al (2008) Vitreous proteomic analysis of proliferative vitreoretinopathy. Proteomics 8:3667–3678PubMedCrossRef

77.

Coral K, Angayarkanni N, Madhavan J et al (2008) Lysyl oxidase activity in the ocular tissues and the role of LOX in proliferative diabetic retinopathy and rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci 49:4746–4752PubMedCrossRef

78.

Symeonidis C, Papakonstantinou E, Souliou E et al (2011) Correlation of matrix metalloproteinase levels with the grade of proliferative vitreoretinopathy in the subretinal fluid and vitreous during rhegmatogenous retinal detachment. Acta Ophthalmol 89:339–345PubMedCrossRef

79.

Shitama T, Hayashi H, Noge S et al (2008) Proteome profiling of vitreoretinal diseases by cluster analysis. Proteomics Clin Appl 2:1265–1280PubMedPubMedCentralCrossRef

80.

Larson BJ, Longaker MT, Lorenz HP (2010) Scarless fetal wound healing: a basic science review. Plast Reconstr Surg 126:1172–1180PubMedPubMedCentralCrossRef

81.

Leung A, Crombleholme TM, Keswani SG (2012) Fetal wound healing: implications for minimal scar formation. Curr Opin Pediatr 24:371–378PubMedPubMedCentralCrossRef

82.

Tsai HW, Wang PH, Tsui KH (2017) Mesenchymal stem cell in wound healing and regeneration. J Chin Med Assoc 17:30168–30165

83.

Horng HC, Chang WH, Yeh CC et al (2017) Estrogen effects on wound healing. Int J Mol Sci 18:E2325PubMedCrossRef

84.

Yannas IV, Tzeranis DS, So PTC (2017) Regeneration of injured skin and peripheral nerves requires control of wound contraction, not scar formation. Wound Repair Regen 25:177–191PubMedPubMedCentralCrossRef

85.

Carre AL, Larson BJ, Knowles JA, Kawai K, Longaker MT, Lorenz HP (2012) Fetal mouse skin heals scarlessly in a chick chorioallantoic membrane model system. Ann Plast Surg 69:85PubMedPubMedCentralCrossRef

Titel: Proliferative Vitreoretinopathie-Prozess – „To heal or not to heal“
verfasst von: Univ.-Prof. Dr. S. Grisanti
S. Priglinger
L. Hattenbach
Publikationsdatum: 16.12.2020
Verlag: Springer Medizin
Schlagwörter: Netzhautablösung
Wachstumsfaktoren
Wachstumsfaktoren
Erschienen in: Die Ophthalmologie / Ausgabe 1/2021
Print ISSN: 2731-720X
Elektronische ISSN: 2731-7218
DOI: https://doi.org/10.1007/s00347-020-01294-0

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Proliferative Vitreoretinopathie-Prozess – „To heal or not to heal“

Zusammenfassung

Hintergrund

Methoden

Ergebnisse

Schlussfolgerung

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Zusammenfassung

Hintergrund

Methoden

Ergebnisse

Schlussfolgerung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Ablatio retinae nach intravitrealer Ocriplasmin-Injektion

Nekrotisierende Skleritis nach Akanthamöbenkeratitis

Erratum zu: Abstractband DOG 2020

Proliferative Vitreoretinopathieprophylaxe

Die proliferative Vitreoretinopathie: das ungelöste Problem

Die „DOG 2020 online“ – erstmals im von-Graefe-Jahr

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde